New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
05:09 EDTCTICCell Therapeutics approves amendment of shareholder rights plan
Cell Therapeutics announced that its board has approved certain amendments to CTI's existing shareholder rights plan to decrease the exercise price of the preferred stock purchase rights under the Rights Plan from $14.00 to $8.00 and to extend the "final expiration date" from the close of business on the third anniversary of January 7, to the close of business on December 3, 2015. The Rights were initially distributed as a dividend on each share of CTI's common stock outstanding on the Record Date and currently trade with each outstanding share of CTI's common stock.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
05:32 EDTCTICCTI BioPharma announces advancement of tosedostat LI-1 trial
Subscribe for More Information
November 23, 2015
09:18 EDTCTICOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Tyson Foods (TSN), up 2.4%... Mallinckrodt (MNK), up 7.4%. ALSO HIGHER: Novocure (NVCR), up 16.8% after announcing new Phase 3 data from Optune study... CTI BioPharma (CTIC), up 12.7% after the initiation of its rolling new drug application to the FDA for pacritinib... Peabody Energy (BTU), up 14.8% after announcing an asset sale... Sarepta Therapeutics (SRPT), up 5.2% following a positive mention in Barron's. DOWN AFTER EARNINGS: Trina Solar (TSL), down 5.6%. ALSO LOWER: Par Pacific (PARR), down 13.2% after pricing its 3.4M registered direct offering at $22.00... Lions Gate (LGF), down 2.9% after the "Hunger Games" finale opens below the series average.
05:39 EDTCTICCTI BioPharma initiates rolling submission of U.S. NDA for pacritinib
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use